Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790412 | 0.83 | MEN1 (0.42) | PIK3CDMEN1KMT2ACHRNB2CHRNA4 | |
| SCHEMBL9705215 | 0.79 | MEN1 (0.48) | MEN1KMT2ACHRNB2CHRNA4LTA4H | |
| SCHEMBL5406202 | 0.78 | PIK3CD (0.44) | PIK3CD | |
| SCHEMBL10289399 | 0.77 | PIK3CD (0.48) | PIK3CD | |
| SCHEMBL12918859 | 0.77 | MEN1 (0.46) | MEN1KMT2ACHRNB2CHRNA4LTA4H | |
| SCHEMBL372755 | 0.76 | PIK3CD (0.43) | PIK3CD | |
| SCHEMBL24315326 | 0.74 | MEN1 (0.43) | MEN1KMT2ACHRNB2CHRNA4LTA4H | |
| SCHEMBL21127230 | 0.74 | MEN1 (0.43) | MEN1KMT2ACHRNB2CHRNA4LTA4H | |
| SCHEMBL21770728 | 0.74 | MEN1 (0.43) | MEN1KMT2ACHRNB2CHRNA4LTA4H | |
| SCHEMBL16668176 | 0.74 | MEN1 (0.43) | MEN1KMT2ACHRNB2CHRNA4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4238206-A | TERTIARY AMINE OR CARBONATE SOLVENT | COLUMBIA GAS SYSTEM SERVICE CORPORATION (US) | 1980-12-09 | — | — | US | claimed |
| US-11827616-B2 | Heterocyclic compounds as pesticides | DISCOVERY PURCHASER CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11377435-B2 | Enzyme-triggered carbon monoxide releasing molecules | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210388196-A1 | GENE DELIVERY CARRIER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-16 | — | — | US | disclosed |
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| US-5698685-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0592511-B1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5506337-A | Morpholino-subunit combinatorial library and method | ANTIVIRALS INC. (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0669927-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5405938-A | Hydrogen bonding an N-heterocyclic-substituted ribose-based polymer to a double-stranded DNA to block genetic activity, to diagnose for pathogens and to aid in genetic engineering | ANTI-GENE DEVELOPMENT GROUP (US) | 1995-04-11 | — | — | US | disclosed |
| WO-1994012517-A1 | SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS | ANTIVIRALS INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5166315-A | Polynucleotides for genetic engineering | ANTI-GENE DEVELOPMENT GROUP (US) | 1992-11-24 | — | — | US | disclosed |
| US-4238206-A | TERTIARY AMINE OR CARBONATE SOLVENT | COLUMBIA GAS SYSTEM SERVICE CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377435-B2 | Enzyme-triggered carbon monoxide releasing molecules | CNDP2, CPN1, JMJD7 | PIK3CD 4778/4885MEN1 3189/4885KMT2A 3936/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | PIK3CD 4136/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-11827616-B2 | Heterocyclic compounds as pesticides | DDT, CHRM1, ACHE | PIK3CD 3422/4885MEN1 724/4885KMT2A 1690/4885 |
| US-20210388196-A1 | GENE DELIVERY CARRIER | PAICS, PBDC1, BCAT1 | PIK3CD 941/4885MEN1 3571/4885KMT2A 2017/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | PIK3CD 4136/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-11696953-B2 | Poly(beta-amino esters) and uses thereof | BCAT1, BCAT2, SNRPE | PIK3CD 2392/4885MEN1 4493/4885KMT2A 2481/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | PIK3CD 4136/4885MEN1 3812/4885KMT2A 4184/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | PIK3CD 3703/4885MEN1 4026/4885KMT2A 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.